The FDA approved KalVista Pharmaceuticals’ pill Ekterly (sebetralstat) to treat acute hereditary angioedema attacks in patients aged 12 and older. This approval comes after a brief delay attributed to FDA resource constraints. Ekterly is the first oral on-demand treatment in a market dominated by injectables. The drug showed symptom relief in a median of 1.3 hours post-dose. Analysts forecast peak U.S. sales of $600 million. Multiple articles detail the approval, trial data, and KalVista’s regulatory discussions.